LVTX Valuation
LAVA Therapeutics NV
$
1.530
- Overview
- Forecast
- Valuation
- Earnings
LVTX Relative Valuation
LVTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LVTX is overvalued; if below, it's undervalued.
Historical Valuation
LAVA Therapeutics NV (LVTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.02. The fair price of LAVA Therapeutics NV (LVTX) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：1.53
Fair
-1.51
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
LAVA Therapeutics NV. (LVTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.32. The thresholds are as follows: Strongly Undervalued below -3.61, Undervalued between -3.61 and -1.96, Fairly Valued between 1.32 and -1.96, Overvalued between 1.32 and 2.96, and Strongly Overvalued above 2.96. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.86
EV/EBIT
LAVA Therapeutics NV. (LVTX) has a current EV/EBIT of 0.86. The 5-year average EV/EBIT is 0.21. The thresholds are as follows: Strongly Undervalued below -3.15, Undervalued between -3.15 and -1.47, Fairly Valued between 1.89 and -1.47, Overvalued between 1.89 and 3.57, and Strongly Overvalued above 3.57. The current Forward EV/EBIT of 0.86 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
LAVA Therapeutics NV. (LVTX) has a current PS of 0.00. The 5-year average PS is 104.31. The thresholds are as follows: Strongly Undervalued below -314.20, Undervalued between -314.20 and -104.95, Fairly Valued between 313.57 and -104.95, Overvalued between 313.57 and 522.83, and Strongly Overvalued above 522.83. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
LAVA Therapeutics NV. (LVTX) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.88. The thresholds are as follows: Strongly Undervalued below -19.60, Undervalued between -19.60 and -9.36, Fairly Valued between 11.12 and -9.36, Overvalued between 11.12 and 21.37, and Strongly Overvalued above 21.37. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.13
P/FCF
LAVA Therapeutics NV. (LVTX) has a current P/FCF of -1.13. The 5-year average P/FCF is -2.23. The thresholds are as follows: Strongly Undervalued below -5.53, Undervalued between -5.53 and -3.88, Fairly Valued between -0.58 and -3.88, Overvalued between -0.58 and 1.07, and Strongly Overvalued above 1.07. The current Forward P/FCF of -1.13 falls within the Historic Trend Line -Fairly Valued range.
LAVA Therapeutics NV (LVTX) has a current Price-to-Book (P/B) ratio of 1.56. Compared to its 3-year average P/B ratio of 1.01 , the current P/B ratio is approximately 54.27% higher. Relative to its 5-year average P/B ratio of 1.11, the current P/B ratio is about 40.11% higher. LAVA Therapeutics NV (LVTX) has a Forward Free Cash Flow (FCF) yield of approximately -75.90%. Compared to its 3-year average FCF yield of -40.75%, the current FCF yield is approximately 86.27% lower. Relative to its 5-year average FCF yield of -34.57% , the current FCF yield is about 119.57% lower.
1.56
P/B
Median3y
1.01
Median5y
1.11
-75.90
FCF Yield
Median3y
-40.75
Median5y
-34.57
Competitors Valuation Multiple
The average P/S ratio for LVTX's competitors is 14.43, providing a benchmark for relative valuation. LAVA Therapeutics NV Corp (LVTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LVTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LVTX in the past 1 year is driven by Unknown.
People Also Watch
LRE
Lead Real Estate Co Ltd
1.580
USD
+3.27%
HUDI
Huadi International Group Co., Ltd.
1.130
USD
+2.73%
KFFB
Kentucky First Federal Bancorp
3.100
USD
-2.33%
CKX
CKX Lands Inc
11.660
USD
-0.77%
PLUR
Pluri Inc
4.860
USD
+2.53%
MXC
Mexco Energy Corp
8.200
USD
-2.73%
BNAI
Brand Engagement Network Inc
0.311
USD
-2.51%
PRZO
Parazero Technologies Ltd
1.590
USD
+3.92%
GFAI
Guardforce AI Co Ltd
1.210
USD
+6.61%
FAQ
Is LAVA Therapeutics NV (LVTX) currently overvalued or undervalued?
LAVA Therapeutics NV (LVTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.02. The fair price of LAVA Therapeutics NV (LVTX) is between to according to relative valuation methord.
What is LAVA Therapeutics NV (LVTX) fair value?
How does LVTX's valuation metrics compare to the industry average?
What is the current P/B ratio for LAVA Therapeutics NV (LVTX) as of Aug 13 2025?
What is the current FCF Yield for LAVA Therapeutics NV (LVTX) as of Aug 13 2025?
What is the current Forward P/E ratio for LAVA Therapeutics NV (LVTX) as of Aug 13 2025?